Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
37 Cards in this Set
- Front
- Back
|
Methotrexate |
Type: folic acid analog Use: breast cancer, osteogenic sarcoma, ALL, Burkkits lymphoma, bladder cancer Adverse effects: nephrotoxicity, mucositis, myelosuppression, pulmonary and hepatotoxicity |
|
|
5-fluorouracil/floxuridine |
Type: pyrimidine analog MoA: complexes with folic acid and inhibits thymidylate synthase Use: breast cancer, colorectal cancer, hepatoma Adverse effects: toxicity when used with folinic acid/leucovorin in people with dihydropyrimidine dehydrogenase deficiency |
|
|
Cytaribine |
Type: pyrimidine analog Use: AML Adverse effects: neurotoxicity, myelosuppresion, megaloblastic anemia |
|
|
Cyclophosphamide |
Type: CCNS alkylating agent PK: must be activated by liver Use: solid tumors, CHOP regimen, neuroblastoma, SLE Adverse effects: nephrotoxicity, chemical cystitis, SIADH |
|
|
Bulsufan |
Type: CCNS alkylating agent Use: CML & AML Adverse effects: pulmonary fibrosis, hyperpigmentation, adrenal suppression, cataracts, thrombocytopenia |
|
|
Carmustine |
Type: nitrosureas alkylating agent Use: CNS cancers, GIT tumors Adverse effects: CNS toxicity |
|
|
Cisplatin |
Type: platinum analog MoA: cross links DNA-> breaks Use: testicular cancer, ovarian cancer, bladder cancer Adverse effect: nephrotoxicity, ototoxicity, peripheral neuropathy |
|
|
Doxorubicin |
Type: cytotoxic antibiotic. MoA: causes breaks in DNA by inhibiting topoisomerase II and by free radical formation Use: Lymphomas, thyroid cancer, sarcomas, solid tumors Adverse effects: heart toxicity |
|
|
Epirubicin |
Type: cytotoxic antibiotic |
|
|
Dactinomycin |
Type: CCNS Cytotoxic antibiotic MoA: Intercalates DNA Use: rhabdomyosarcoma, Wilms tumor, ewings tumor, kaposi sarcoma Adverse effects: hematopoietic suppression, pancytopenia, |
|
|
Bleomycin |
Type: cytotoxic antibiotic MoA: fragments DNA Use: Hodgkin's disease, testicular cancer Adverse effect: lung toxicity, hyperpigmentation |
|
|
Vincristine |
Type: vinca alkaloid (CCS) MoA: prevent assembly of microtubules Use: leukemias, part of CHOP, rhabdomyosarcoma, neuroblastomas Adverse effect: peripheral neuropathy, constipation (paralytic ileus) |
|
|
Vinblastine |
Type: vinca alkaloid Use: testicular cancer, ABVD regimen Adverse effects: leucopenia, neutropenia |
|
|
Etoposide |
Type: epidophyllotoxin MoA: inhibits topoisomerase II Use: testicular cancer, diffuse lymphomas, Hodgkin's disease, oat cell carcinoma Adverse effects: hypersensitivity, hepatic and renal toxicity, AML, myelosuppression |
|
|
Topotecan |
Type: topisomerase 1 inhibitor Use: ovarian and cervical cancer, colorectal cancer Adverse effects: neutropenia |
|
|
Paclitaxel |
Type: taxane MoA: inhibit microtubule disassembly Use: ovarian cancer, breast cancer, lung, neck and bladder cancers Adverse effect: hypersensitivity, neutropenia, arrhythmia, peripheral neuropathy |
|
|
Docetaxel |
Type: taxane Use: ovarian and cervical cancer, prostate cancer Adverse effects: neutropenia, hypersensitivity, arrhythmia |
|
|
Tamoxifen |
Type: SERM Use: breast cancer treatment and prophylaxis Adverse effects: vaginal bleeding, hypercalcemia, peripheral edema, increased risk of endometrial cancer |
|
|
Fulvestrant |
Type: estrogen receptor antagonist Use: breast cancer in post menopausal women that are resistant to tamoxifen |
|
|
Anastrazole |
Type: aromatase inhibitor Use: breast cancer in postmenopausal women who are resistant to tamoxifen |
|
|
Flutamide |
Type: nonsteroidal androgen antagonist Use: prostate cancer |
|
|
Cyproterone |
Type: steroidal androgen receptor antagonist Use: prostate cancer |
|
|
Finasteride |
Type: 5alpha dedicates inhibitor Use: prostate cancer |
|
|
Hydroxyurea |
Type: ribonucleotide reductase inhibitor Use: myeloproliferative disorders |
|
|
Asparaginase |
Type: enzyme Use: ALL Adverse effects: hypersensitivity, toxicity |
|
|
Mesna |
Type: antidote Use: chemical cystitis |
|
|
Demeclocycline |
Type: antidote Use: SIADH |
|
|
Dimethylsulfoxide |
Type: antidote Use: swabbed on skin in event of extravasation |
|
|
Dexrazoxane |
Type: antidote Use: doxorubicin induced cardiomyopathy |
|
|
Amifostine |
Type: antidote Use: cisplatin antidote |
|
|
Imatinib mesylate |
Type: TyrK inhibitor (Bcr/Abl) Use: CML, gastrointestinal tumors |
|
|
Sutinib |
Type: TyrK inhibitor |
|
|
Erlotinib |
Type: TyrK inhibitor Use: pancreatic cancer, lung cancer |
|
|
Rituximab |
Type: anti-CD20 monoclonal Ab Use: non Hodgkin's lymphoma |
|
|
Trastuzumab |
Type: herceptin monoclonal Ab Use: breast cancer Adverse effects: ventricular dysfunction |
|
|
Bevacizumab |
Type: VEGF inhibitor Use: metastatic colorectal carcinoma, metastatic breast cancer, macular degeneration |
|
|
Cladribine |
Class: adenosine deaminase inhibitor Use: hairy cell leukemia |
